Errata

This article refers to:

Historical aspects and milestones in the development of effective treatment for hairy cell leukemia

Thalidomide in Myelofibrosis with Myeloid Metaplasia: A Pooled-analysis of Individual Patient Data from Five Studies

Erratum 1

The publishers would like to apologise for an error that occurred in a recent supplement of Leukemia & Lymphoma, October 2009; 50(S1): 2–7.

Historical aspects and milestones in the development of effective treatment for hairy cell leukemia

MARTIN S. TALLMAN¹ & AARON POLLIACK²

Due to a typesetting error the abstract should have read as follows:

Abstract

Hairy cell leukemia (HCL) is a rare B-cell lymphoproliferative disorder, but is gratifying to treat for both physicians and patients. During the 50 years since its initial description as a clinical entity, hematologists have been fascinated by the bizarre appearance of the malignant cell with its hair-like projections. Therapeutic strategies have evolved from splenectomy to interfere to the purine analogues which have become the treatments of-choice and are very effective. Immunoconjugate Therapy with BL22 (anti-CD22 antibody linked to truncated to Pseudomonas exotoxin) represents the newest milestone in the development of effective treatment for hairy cell leukemia.

Erratum 2

The publishers would like to apologise for an error that occurred in Leukemia & Lymphoma, 2002 Vol. 43 (12), pp. 2301–2307.

Thalidomide in Myelofibrosis with Myeloid Metaplasia: A Pooled-analysis of Individual Patient Data from Five Studies

BAROSI GIOVANNI^a,*, ELLIOTT MICHELLE^b, CANEPA LETIZIA^c, BALLERINI FILIPPO^c, PICCALUGA PIER PAOLO^d, VISANI GIUSEPPE^e, MARCHETTI MONIA^a, POZZATO GABRIELE^f, ZORAT FRANCESCA^f and TEFFERI AYALEW^b

We have been informed that the authors should read as follows:

GIOVANNI BAROSI^a,*, MICHELLE ELLIOTT^b, LETIZIA CANEPA^c, FILIPPO BALLERINI^c, PIER PAOLO PICCALUGA^d, GIUSEPPE VISANI^e, MONIA MARCHETTI^a, GABRIELE POZZATO^f, FRANCESCA ZORAT^f and AYALEW TEFFERI^b